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P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overex-
pressed in a number of different cancers and some studies show that P-gp overexpression
can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate
if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by
tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were
ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray
for these cell lines. P-gp expression was determined by western blot and activity deter-
mined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp
to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in
cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice
were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor
and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expres-
sion correlates with resistance to PF-309 treatment in vitro and the expression and activity
of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased
the sensitivity of resistant cells, resulting in a 4–100-fold decrease in the IC50s. Eleven
cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line
xenografts, we found a significant correlation between ABCB1 gene expression profiles
and tumor response. We evaluated tumor and plasma concentrations for eight tumor mod-
els (three cell line xenografts and five PDTX models) and a significant correlation was found
between tumor concentration and response. Additionally, we show that tumor concentra-
tion is approximately fourfold lower in tumors that express P-gp, verified by western blot.
Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the
expression of tumor P-gp.
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INTRODUCTION
Multi-drug resistance (MDR) proteins and their expression or
overexpression has been correlated to poor prognosis, therapeu-
tic resistance, and relapse in various cancer types (Sinicrope et al.,
1994; Fardel et al., 1996; Sekine et al., 2009; Zajchowski et al., 2012).
P-glycoprotein (P-gp), encoded by ABCB1 (also known as MDR1),
is the most well-studied energy-dependent transmembrane efflux
protein, with a wide range of structurally diverse substrates (Linn
and Giaccone, 1995; Fardel et al., 1996; Gottesman et al., 2002; Lee
et al., 2010). Breast cancer resistance protein (BCRP), encoded by
ABCG2, is another drug efflux transporter that has been shown to
play a role in resistance to various cancer therapeutics. P-gp and
BCRP are expressed in some normal tissues, to serve as protective
barriers (i.e., in brain, placenta, testes) or for detoxification (i.e.,
in liver, kidney intestine), and is expressed at high levels in numer-
ous tumor types (Gottesman et al., 2002; Leonard et al., 2003; Lee
et al., 2010). Typically, tumors derived from epithelial tissues that
normally express P-gp such as colorectal, hepatocellular, and renal
cancer, frequently express high levels of P-gp (Linn and Giaccone,
1995; Gottesman et al., 2002; Leonard et al., 2003).
In oncology, resistance to therapy is a critical issue and can be
due to molecular or genetic alterations that affect sensitivity or
impair drug delivery. The overexpression of MDR proteins has
been correlated with both de novo (Sinicrope et al., 1994; Sekine
et al., 2009) and acquired (Zajchowski et al., 2012) resistance to
therapeutics in cancer. The presence or upregulation of MDR pro-
teins has been demonstrated in a variety of cancer types and has
been shown to contribute to reduced intracellular concentration
of substrates (McGrath and Center, 1988). Extensive preclinical
and clinical studies have focused on MDR proteins in cancer resis-
tance to chemotherapeutics (Bellamy et al., 1988; McGrath and
Center, 1988; Jang et al., 2001a,b; Leonard et al., 2003; Murray
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et al., 2012); however, the role of MDR proteins in resistance to
the newer signal transduction inhibitors is not well-understood.
PF-3758309 (PF-309) is a novel pyrrolopyrazole inhibitor of p-
21 activated kinase (PAK) that has demonstrated low nanomolar
activity in a range of cancer types (Murray et al., 2010). The PAK
family of proteins, PAKs 1–3 (group I) and PAKs 4–6 (group II),
play a role in the regulation of cell motility, survival, angiogenesis,
and proliferation (Kumar et al., 2006; Eswaran et al., 2009; Molli
et al., 2009). Additionally, PAKs are altered in a variety of can-
cers, and increased migratory potential, anchorage-independent
growth, oncogenic transformation, and metastasis has been tied
to overexpression of PAKs (Eswaran et al., 2009; Murray et al.,
2010); making PAKs an attractive therapeutic target (Kumar et al.,
2006; Eswaran et al., 2009; Molli et al., 2009).
The current focus in oncology is to design and develop agents
that target signal transduction pathways. Often times these agents
are only beneficial to a select population of patients and identi-
fication of biomarkers for the prediction of response has gained
significant attention (Banck and Grothey, 2009; Pitts et al., 2010;
Prenen et al., 2010; Siddiqui and Piperdi, 2010; Tentler et al.,
2010; Heakal et al., 2011; Shaw et al., 2011). However, for com-
pounds that are MDR transporter substrates, it may be beneficial to
also: (1) determine how strongly the compound efficacy is altered
by the presence of transporters; and (2) use transporter expres-
sion/activity information in conjunction with molecular classifiers
to select patients with the highest likelihood to benefit from the
therapy. In the studies presented here we show that PF-309 is a sub-
strate for the MDR transporters P-gp and BCRP, and we sought
to determine if PF-309 activity is influenced by the presence of
tumor transporters in in vitro and in vivo models of colorectal
cancer (CRC). CRC is a cancer type in which P-gp overexpres-
sion is commonly observed (Linn and Giaccone, 1995) and PAKs
have been shown to be overexpressed and play a role in disease
progression (Carter et al., 2004; Kumar et al., 2006; Tabusa et al.,
2013).
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
PF-3758309 (molecular weight 490.63) was provided by Pfizer,
Inc (La Jolla, CA, USA). PF-309, CP-100356, and Ko143 stock
solutions for in vitro experiments were prepared in DMSO (Fisher
Scientific, Fairlawn, NJ, USA). All other materials used were pur-
chased from either Fisher Scientific (Fairlawn, NJ, USA) or Sigma
(SLouis, MO, USA) unless specified.
CELLS AND CULTURE CONDITIONS
All colorectal, breast, and lung cancer cell lines, except GEO, were
all obtained from ATCC (Manassas, VA, USA). GEO cells were a
generous gift from Dr. Fortunato Ciardiello (Cattedra di Oncolo-
gia Medica, Dipartimento Medico-Chirurgico di Internistica Clin-
ica e Sperimentale “F Magrassi e A Lanzara,” Seconda Univer-
sità degli Studi di Napoli, Naples). All cells, except GEO, were
grown in RPMI medium supplemented with 10% fetal bovine
serum, 1% non-essential amino acids, 1% penicillin/streptomycin.
GEO cells were grown in DMEM/F12 supplemented with 10%
fetal bovine serum, 1% non-essential amino acids, and 1%
penicillin/streptomycin. All cells were maintained at 37˚C in a
humidified incubator with 5% CO2. Cells were routinely screened
for the presence of mycoplasma (MycoAlert, Cambrex Bio Sci-
ence, Baltimore, MD, USA) and were tested and authenticated in
the University of Colorado Cancer Center DNA Sequencing and
Analysis Core. CRC cell line DNA was tested using the Profiler Plus
Kit (Applied Biosystems, Foster City, CA, USA) and compared to
that from the ATCC. All in vitro drug treatments were conducted
with the use of complete growth media.
MDCKII-LE, MDR1-MDCK, AND BCRP-MDCKII-LE TRANSWELL ASSAYS
Permeability and transporter substrate assays were performed as
previously published (Feng et al., 2008; Callegari et al., 2011; Di
et al., 2011). Permeability assays were conducted in MDCKII-LE
cells, which were generated by isolation of a subpopulation of cells
with low expression of endogenous P-gp (Feng et al., 2008; Calle-
gari et al., 2011; Di et al., 2011). The use of MDCKII-LE cells are
used to measure the passive permeability of compounds in place
of MDCK wild-type or Caco-2 cells since both MDCK wild-type
and Caco-2 cells are known to have some level of endogenous
transporter expression which can affect the permeability mea-
surement. P-gp efflux was determined in MDR1-MDCK cells and
BCRP efflux was measured in BCRP-MDCKII-LE cells.
CELLS PROLIFERATION ASSAYS
Cytotoxic/proliferation effects were determined using the sul-
forhodamine B (SRB) assay (Skehan et al., 1990) or by resazurin.
Briefly, cells in logarithmic growth phase were transferred to 96
well flat bottom plates with lids. One-hundred microliter cell
suspensions containing 1500–5000 viable cells were plated into
each well and incubated overnight prior to exposure with increas-
ing concentrations of PF-309 for 3–5 days, dependent upon cell
type. Media was removed and cells were fixed with cold 10%
trichloroacetic acid for 30 min at 4˚C. Cells were then washed with
water and stained with 0.4% SRB (Fisher Sci., Pittsburgh, PA, USA)
for 30 min at room temperature, washed again with 1% acetic acid,
followed by stain solubilization with 10 mM tris at room temper-
ature. The plate was then read on a plate reader (Biotek Synergy 2,
Winooski, VT, USA) set at an absorbance wavelength of 565 nm.
Cell proliferation curves were derived from the raw absorbance
(OD) data. For P-gp and BCRP inhibition assays, cells were incu-
bated with increasing concentrations of PF-309 in the presence or
absence of 0.625µM CP-100356 or 0.8µM Ko143 for 72 h then
assayed by SRB or CellTiter-Glo®(Promega).
WESTERN BLOT
Cells were seeded into 6-well plates 24 h prior to harvest. Cells were
scraped into RIPA buffer containing protease inhibitors, EDTA,
NaF, and sodium orthovanadate. Total protein was determined
(BioRad Dc Protein Assay, BioRad, Hercules, CA, USA) and 50µg
of total protein was loaded onto a 4–12% gel, electrophoresed
and transferred to Immobilon-P (Millipore, Bedford, MA, USA).
Membranes were blocked for 1 h at room temperature with 5%
non-fat dry milk in TBS containing tween-20 (0.1%) then incu-
bated overnight at 4˚C with antibodies to P-gp (1:250 dilution,
Santa Cruz) or actin (1:1000 dilution, Cell Signaling, Beverly, MA,
USA). Following primary antibody incubation, blots were washed
in TBS-Tween (0.1%), then incubated with the appropriate sec-
ondary antibody at 1:15,000 (LI-COR, Lincoln, NE, USA) for 1 h at
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room temperature. Following three additional washes, blots were
developed using the Odyssey Infrared Imaging System (LI-COR
Biosciences).
RHODAMINE UPTAKE ASSAY
Rhodamine uptake/efflux assays were conducted similarly to a pre-
viously published report (Lee et al., 1994). Cells were seeded into
6-well plates 24 h prior to the efflux assay. Rhodamine (3µM) or
rhodamine+CP-100356 (1µM) was added to plated cells. After
1 h, rhodamine containing media was removed and fresh media or
media+CP-100356 was added to cells for 1 h of efflux. Cells were
harvested, washed and flow cytometry performed to measure the
fluorescence intensity per 5000 cells.
shRNA KNOCKDOWN
The pGIPZ Pgp-specific shRNA expression cassettes, along with
control shRNA plasmids including the original pGIPZ vector
were purchased from Open Biosystems (Birmingham, AL, USA).
Pgp-specific shRNA plasmids were co-transfected with packaging
plasmids into HEK293T to produce lentiviral particles, accord-
ing to manufactures instructions. Stable clones were generated
by transducing CRC cell lines with lentiviral particles containing
Pgp-specific shRNAs. Seventy-two hours after transduction, the
cells were placed under selection with 2.5µg/mL of puromycin,
splitting 1:5 when the cells reached confluency. Multiple clones
from the same transfection were pooled and grown under
puromycin selection. Successful knockdown of specific genes and
gene products was confirmed by semi-quantitative RT-PCR and
immunoblotting with specific antibodies. Each experiment was
conducted in triplicate.
ANIMALS
Female 5–6-week-old athymic nude mice were purchased from
Harlan Sprague Dawley. Animals were housed (three to five per
cage) in polycarbonate cages and kept on a 12 h light/dark cycle.
Animals were allowed to acclimate for at least 7 days before any
handling. Food and water were given ad libitum. All studies were
conducted at the University of Colorado Anschutz Medical Cam-
pus in accordance with the National Institutes of Health guidelines
for the care and use of laboratory animals, and animals were
housed in a facility accredited by the American Association for
Accreditation of Laboratory Animal Care.
XENOGRAFT STUDIES
Cell line xenografts
For cell line xenografts, CRC cells were harvested in exponential
phase growth and resuspended in a 1:1 mixture of serum-free
RPMI 1640 and Matrigel (BD Biosciences). Five to ten million
cells per mouse were injected subcutaneously into the flank using
a 23-gauge needle. Mice were monitored daily for signs of toxicity
and were weighed twice weekly. Tumor size was evaluated twice
per week by caliper measurements using the following formula:
tumor volume= length×width2× 0.52. When tumors reached
200–300 mm3 mice were randomized into two groups with at least
10 tumors per group. Mice were then treated for 14–28 days (until
control tumor volume reach∼1500 mm3) with either vehicle con-
trol (0.5% methylcellulose), or PF-3758309 (25 mg/kg) twice daily
by oral gavage.
Patient derived tumor xenografts
For patient tumor xenografts, surgical specimens of patients
undergoing either removal of a primary or metastatic tumor
at the University of Colorado Hospital are implanted subcuta-
neously into five mice for each patient with a 10-G trochar. After
a subsequent growth and passage in mice, tumors are excised,
and expanded into cohorts for treatment (n= 6–15 per group).
Mice were treated with PF-309 or vehicle (0.5% methylcellulose)
for 22–56 days (until control tumor volume reach ∼1500 mm3)
twice daily (BID) by oral gavage (PO). Monitoring of mice and
measurements of tumors were conducted as described above.
GENE EXPRESSION PROFILES
CRC cell lines gene expression profiles
Cells were plated at 2× 106 in 6-well plates 24 h prior to har-
vest. After 24–72 h cells were rinsed twice with PBS, and RNA
was prepared using a RNeasy Plus mini kit (Qiagen, Valencia, CA,
USA). RNA stabilization, isolation, and microarray sample label-
ing were carried out using standard methods for reverse transcrip-
tion and one round of in vitro transcription. Total RNA isolated
from CRC cell lines was hybridized on Affymetrix U133 Plus 2.0
microarrays. The sample preparation and processing procedure
was performed as described in the Affymetrix GeneChip®Expres-
sion Analysis Manual (Affymetrix Inc., Santa Clara, CA, USA).
In addition, CRC cell line gene expression profiles were obtained
from the GlaxoSmithKline (GSK) genomic profiling data via the
NCI cancer Bioinformatics Grid (caBIG®) website1. These data
were also profiled using Affymetrix U133 Plus 2.0 gene arrays
in triplicates. To integrate the data generated from our lab and
GSK, absolute intensity signals from the microarray gene expres-
sion profiles were extracted and probe sets representing the same
gene were collapsed based on maximum values. Next, the gene
expression levels were converted to a rank-based matrix and stan-
dardized (mean= 0, standard deviation= 1) for each microarray.
Using this pre-processing method, the same cell lines from differ-
ent data sets were clustered based on their gene expression profiles.
Data analyses were performed on this rank-based matrix.
CRC cell line xenograft gene expression profiles
Total RNA isolated from CRC cell line xenografts was hybridized
on Affymetrix HuGene 1.0 ST microarrays. The sample prepara-
tion and processing procedure was performed as described in the
Affymetrix GeneChip®Expression Analysis Manual (Affymetrix
Inc., Santa Clara, CA, USA). Gene expression was normalized by
the RMA method using Affymetrix Power Tools.
Epithelial and mesenchymal genetic signature
For determining the epithelial to mesenchymal signature, epithe-
lial (E; CLDN2, CDH1, RAB25, CLDN3, and CDH17 ), and mes-
enchymal (M) genes (CALD1, VIM, ANK2, and ZEB1) derived
from the PAK inhibitor (see companion article: (Pitts et al., 2013).
The expressions of these genes were ranked normalized within cell
line and then Z-normalization was performed on this rank-based
matrix. An average value is computed for the E-genes and M-
genes. Gene expression of the ABCB1 was also obtained by ranked
1(https://cabig.nci.nih.gov/)
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normalized. To visualize the heatmap, we used the matrix2png
software (Pavlidis and Noble, 2003) where rows and columns
represent genes and cell lines, respectively. Red and green colors
represent high and low expression, respectively.
PLASMA AND TUMOR CONCENTRATIONS
Plasma and tumor samples were collected 1 h post treatment at the
end of therapeutic studies or 6 h post treatment for P-gp tumor
concentration studies. PF-309 was measured in mouse plasma and
tumor tissue using a validated LC/MS/MS assay carried out by
the University of Colorado Cancer Center Pharmacology Shared
Resource. Positive ion electrospray ionization (ESI) mass spectra
were obtained with a 3200 QTrap triple quadrupole mass spec-
trometer (Applied Biosystems Inc., Foster City, CA, USA) with a
turboionspray source interfaced to an Agilent 1200 Series binary
HPLC system (Agilent Technologies Inc., Santa Clara, CA, USA),
and a HTC-PAL auto-sampler (LEAP Technologies, Carrboro,
NC, USA). Samples were chromatographed with a Waters Sunfire
2.5µm C18 column (4.6× 50 mm; Waters Corp., Milford, MA,
USA) with a Phenomenex C18 filter frit guard cartridge (Phe-
nomenex, Torrance, CA, USA). The LC elution was done with a
gradient starting at 10% Acetonitrile with 0.1% formic acid:90%
0.1% formic acid held for 1.5 min followed by a 1-min linear gra-
dient to 98% Acetonitrile with 0.1% formic acid: 2% 0.1% formic
acid at a flow rate of 750µl/min and a sample volume of 50µl.
The total analysis time was 5.5 min.
The mass spectrometer settings were: source tempera-
ture, 600˚C, ion spray voltage, 4500 V, source gas, 50, cur-
tain gas (CUR), 10, collision gas (CAD), low, and nee-
dle position 3. Transition specific parameters used were
491.2→ 284.2/491.2→ 148.3/372.2→ 176.1: declustering poten-
tial (DP),46.32/46.54/56.86 V,exit potential (EP),6.45/3.23/4.08 V,
collision cell entrance potential (CEP), 25.92/27.80/20.56 V, colli-
sion energy (CE), 40.00/53.10/32.75 V, collision cell exit potential
(CXP), 0.42/1.47/2.72 V. Samples were quantified by the internal
standard reference method in the MRM mode by monitoring for
PF-3758309 transitions of m/z 491.2→ 284.2 and 491.2→ 148.3,
and for the internal standard (trazodone) of m/z 372.2→ 176.1.
Unknown, standard and quality control samples were extracted
from mouse plasma or tumor homogenates (100 mg/ml) by the
sequential addition of 5µl 500 ng/ml internal standard (tra-
zodone), 250µl acetonitrile:methanol (3:1) to 50µl plasma/tumor
homogenate. Samples were then vortexed for 5 min followed
by centrifugation for 10 min at 17,000 rpm. 200µl of super-
natant was then transferred to a microcentrifuge tube followed
by the addition of 400µl 0.1% formic acid followed by vortex-
ing (5 min) and centrifugation (5 min at 13,300 rpm) and the
supernatant collected (600µl) and transferred to auto-sampler
vials. The average accuracy and precision based on analysis of
quality control samples was 93.1 and 98.7% for plasma samples
(range: 1–2500 ng/mL) and 91.9 and 98.2% for tumor (range:
5–5000 ng/mL).
DATA ANALYSIS
Statistical analysis was performed using GraphPad Prism Software
version 4.02 (La Jolla, CA, USA). For comparisons of two groups
an un-paired t -test was performed. For correlations, a Spearman
correlation was used. P values< 0.05 were considered statistically
significant.
RESULTS
PF-3758309 IS A SUBSTRATE FOR P-GLYCOPROTEIN AND BREAST
CANCER RESISTANCE PROTEIN
MDCKII-LE, MDR1-MDCK, and BCRP-MDCKII-LE transwell
assays were performed to determine the permeability and trans-
porter efflux of PF-309 in vitro (Table 1). The permeability of
PF-309 was determined to be 0.9× 10−6 cm/s in MDCKII-LE cells
(mean of two replicates is presented). As previously described
(Feng et al., 2008), in MDCKII-LE cells a compound with a
donor to receiver (A→B) flux of <5× 10−6 cm/s is classified
as having low permeability. Compounds with A→B flux of 5–
15× 10−6 cm/s are classified as moderately permeable and com-
pounds >15× 10−6cm/s are considered to be highly permeable.
Therefore, PF-309 is classified as a poorly permeable compound
by the MDCKII-LE assay.
MDR1-MDCK and BCRP-MDCKII-LE transwell assays mea-
sure the effect of P-gp and BCRP, respectively, on transcellular
flux. The efflux ratio, ratio of the B→A flux to the A→B flux,
of PF-309 was measured to be 34.9± 7.9 in the MDR1-MDCK
assay, indicating it is a strong substrate for P-gp. PF-309 was
also determined to be substrate for BCRP as the efflux ratio
was measured to be 7.6± 1.1. As a reference, compounds with
efflux ratios >2 are considered to be substrates (Callegari et al.,
2011).
P-GLYCOPROTEIN EXPRESSION CORRELATES WITH IN VITRO ACTIVITY
Since PF-309 appeared to be a strong P-gp and BCRP substrates,
we sought to evaluate if the transporters influenced sensitiv-
ity in vitro. We evaluated the sensitivity of CRC cell lines to
PF-309 treatment in a panel of 27 lines. Cells were exposed to
PF-309 at a range of concentrations for 72 h and cell content
measured by SRB assay (see Pitts et al., 2013). From the 27
lines tested, we selected lines that had approximately 100-fold
difference in IC50 and examined the ABCB1 and ABCG2 gene
expression profiles (Figure 1). We found a significant correla-
tion between relative ABCB1 levels in CRC cell lines and their
respective IC50s (p= 0.01); but, no correlation was found between
relative ABCG2 and IC50s (p= 0.3). A similar analysis was con-
ducted in an expanded panel of 71 cell lines to include CRC,
breast, and non-small cell lung cancer cell lines (Figure 2). PF-
309 activity was evaluated in CRC, breast, and lung cancer lines
since PAKs have been shown to be overexpressed in these cancers
(Kumar et al., 2006; Ong et al., 2011). Again, a significant corre-
lation between relative ABCB1 levels and IC50 values was found
(p< 0.0001).
Table 1 | PF-3758309 permeability and efflux.
A→B
(cm/s)
B→A
(cm/s)
Efflux
ratio
MDCK-MDR1 efflux 0.33±0.06 11.5±1.5 34.9±7.9
BCRP-MDCKII-LE efflux 1.4±0.1 10.5±1.3 7.6±1.1
MDCKII-LE permeability assay 0.9×10−6 cm/s
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FIGURE 1 | Correlation ofABCB1 andABCG2 expression and
resistance in a panel of CRC cell lines. Anti-proliferative effects of PF-309
was determined in CRC cell lines treated with various concentrations for
72 h by SRB assay. Cell line IC50 values were calculated and values below
12.5 nM were classified as sensitive and cell lines with an IC50 greater than
1µM were classified as resistant (∼100-fold difference in activity). A
heatmap for ABCB1 and ABCG2 expression in the panel of lines was
generated (red represents high expression and green represents low).
Spearman correlation of ABCB1 relative expression and IC50 values
showed a significant correlation (p= 0.01) while ABCG2 relative expression
did not correlate with activity (p=0.3).
In a subset of CRC cell lines, western blotting, and rhodamine
efflux was used to verify the expression and function of P-gp. Con-
sistent with the gene expression data, the sensitive cell lines, RKO,
HCT116, and Colo205 show no P-gp expression and no func-
tional P-gp, and the resistant lines, SW948, HCT15, and SW1116
express functional P-gp (Figures 3A,B). Next we sought to deter-
mine if P-gp inhibition could increase the potency of PF-309 in a
subset of the CRC cell lines. Proliferation assays were performed
with PF-309 in the presence and absence of the P-gp inhibitor CP-
100356 (0.625µM). CP-100356 is a transporter specific (P-gp and
BCRP) compound that does not affect metabolism, unlike vera-
pamil and cyclosporine (Kalgutkar et al., 2009). CP-100356 was
able to cause a 4–100-fold change in the IC50 of PF-309 in five
out of the six CRC cell lines (Table 2). CP-100356 did not directly
cause anti-proliferative effects at 0.625µM and was unable to alter
the IC50 of a compound (PF-XXX) that is not a P-gp substrate
(IC50= 440 nM alone compared to 390 nM with CP-100356). In
addition to pharmacologic inhibition of P-gp, we determined that
shRNA knockdown of P-gp resulted in a four to six fold shift in
the IC50 (Figure 4).
Since, CP-100356 affects both P-gp and BCRP, we also deter-
mined if BCRP inhibition alone would alter cell line sensitivity.
Proliferation assays were performed with PF-309 in the presence
and absence of the BCRP inhibitor Ko143 (0.8µM). Ko143 was
able to enhance the efficacy of PF-309, however only marginally.
In HCT15 and Caco-2 cells, the IC50s of PF-309 in the presence
of Ko143 was shifted to approximately 500 nM (less than two fold
change) and 150 nM (two fold change), respectively.
IN VIVO EFFICACY OF PF-3758309 CORRELATES WITH TUMOR ABCB1
EXPRESSION
Human tumor xenograft models were used to evaluate the efficacy
of PF-309 in vivo. Eleven different CRC cell line tumor xenografts
were treated with 25 mg/kg PF-309 twice daily by oral gavage for
14–28 days (until control tumor volumes reached ∼1500 mm3).
Tumor volumes were measured throughout the study and the %
growth inhibition was calculated from the average end of study
tumor volumes by:
% Growth Inhibition =(
average control volume− average treated volume)
average control volume
× 100%
A range of responses was observed with the maximal growth
inhibition being 52% (Figure 5). We evaluated the tumor growth
inhibition data and ABCB1 and ABCG2 gene expression data and
found a significant correlation with ABCB1 (p= 0.02), but not
with ABCG2 (p= 0.7), reinforcing what was observed in vitro.
Note that ABCB1 and ABCG2 gene expression from baseline
(untreated) cell line tumor xenografts was used for this analysis
and not the cell line gene expression data.
IN VIVO EFFICACY CORRELATES WITH TUMOR CONCENTRATION AND
P-GLYCOPROTEIN AFFECTS TUMOR CONCENTRATION OF PF-3758309
In addition to the cell line xenografts, we also treated 12 different
patient derived tumor xenograft (PDTX) CRC models with PF-309
(Figure 6). We were unable to assess how ABCB1 gene expression
correlated with efficacy in these models. The PDTX models are
propagated in vivo, are not immortalized, and are not grown in
in vitro culture. Therefore, we have observed some changes in
ABCB1 gene expression in some of our models over time and the
direction of the change is not consistent (data not shown). In
lieu of analyzing gene expression profiles, we sought to determine
if tumor concentration correlated with in vivo response. Tumor
and plasma sample pairs were collected from animals at the end
of study for eight tumor models (three cell line xenografts and
five PDTX models) and concentrations of PF-309 were measured.
Table 3 shows the paired tumor and plasma concentration data
and the calculated tumor to plasma ratio for individual animals
(n= 2–4 per tumor type) for the different tumor types (each line
represents measurements from individual animals). Significant
correlations (p< 0.003) were found between both tumor concen-
tration and response and tumor to plasma ratios and response
(Table 3).
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FIGURE 2 | Correlation ofABCB1 expression and resistance in an
expanded panel of cell lines. A heatmap for ABCB1 expression in a panel of
CRC, breast, and non-small cell lung cancer cell lines was generated and IC50
values established by resazurin (red represents high expression and
blue/black represents low). Again, a significant correlation between ABCB1
gene expression and IC50 was found (p<0.0001).
Finally, we determined if the presence of P-gp affects tumor
concentration. We evaluated the tumor concentration in two
tumor xenograft lines with high ABCB1 gene expression (SW480
and HCT15) and two tumor xenografts with low ABCB1 gene
expression (GEO and HCT116). Tumors from animals treated
with a single dose of 25 mg/kg PF-309 were collected 6 h post treat-
ment and concentrations analyzed. In tumors with expected high
tumor P-gp a ∼four fold lower concentration was observed than
the tumors with low ABCB1 expression (Figure 7A). Tumors were
also analyzed by western blot to confirm the presence or absence
of P-gp, which agreed with the gene expression data (Figure 7B).
DISCUSSION
Numerous agents, approved and in development, are substrates
for transporters, and it may not be clear yet the role that MDR
transporters play in resistance to these therapies. The overall goal
of the study described herein was to establish if PF-309 efficacy is
influenced by the presence of tumor transporters. We believe that
the in vitro and in vivo data presented here strongly suggests that
tumor uptake of PF-309 is a key determinant of efficacy and that
tumor P-gp expression affects this.
PF-309 is a strong P-gp substrate and we demonstrated in a
panel of cell lines that resistance to PF-309 significantly correlated
with ABCB1 expression. We also showed that PF-309 is a BCRP
substrate, but no correlation was found between ABCG2 relative
expression and in vitro or in vivo efficacy in CRC models. We
demonstrated through knockdown and pharmacologic inhibition
of P-gp, that activity of PF-309 could be enhanced 4–100-fold in
high P-gp expressing lines. In vivo, we were able to significantly
correlate the efficacy in CRC models to tumor uptake of PF-309
and found a significant correlation between ABCB1 expression
and response in CRC cell line xenograft models. In the cell line
xenograft models, we found four models with statistically signif-
icant differences in end of study tumor volumes compared with
controls that demonstrated >40% average tumor growth inhi-
bition (Figures 5A,B). All four of those tumor lines, HCT116,
Colo201, Colo205, and RKO show low ABCB1 gene expression.
Conversely, there were four cell line xenograft models with<40%
average tumor growth inhibition, all of which had high ABCB1
gene expression levels.
Although the in vitro data supports a strong influence of P-gp
on the activity of PF-309, in vivo data is a little less clear. Of the
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FIGURE 3 | Expression and activity of P-gp in a panel of CRC cell lines.
(A) The presence of P-gp was determined in three sensitive and three
resistant cell lines by western blot. Protein expression in this panel of lines
corresponded to ABCB1 expression. (B) The activity of P-gp in the same
panel of cell lines was verified by rhodamine uptake studies. Rhodamine
(Rho) is effluxed by P-gp, so in lines with functional P-gp a lower
fluorescence signal is detected. Administration of a P-gp inhibitor,
CP-100356 (CP), increases the fluorescence signal in lines with function
P-gp but does not affect the signal in lines without P-gp.
11 cell line xenografts treated, the presence or absence of P-gp
appears to coincide with effect in eight of the models. However,
in the remaining three xenograft tumor lines, SW480, GEO, and
SW48, the data was inconsistent. In these models we found that
similar and reasonable average growth inhibition (42,42,and 45%)
was obtained, although the end of study tumor volumes between
treated groups and controls were not statistically significant, but
two of the three models had high ABCB1 gene expression and one
did not. As a result, we conducted a study to determine if P-gp was
present and if the presence of P-gp altered tumor concentration.
For this study we selected two cell line xenografts with results that
were not consistent with ABCB1 expression (SW480 and GEO)
and two with consistent results (HCT15, and HCT116). What we
found was that P-gp expression agreed with ABCB1 expression
data and that tumors that expressed P-gp had a lower concen-
tration of PF-309 (Figures 7A,B). This data indicates that GEO
and SW480 tumors require different concentrations of PF-309 to
achieve the same level of activity.
Through studies conducted prior to and in conjunction with
this work (see companion article (Pitts et al., 2013), we identified
additional markers associated with sensitivity to PF-309 in models
of CRC and found that cells and tumors with an epithelial geno-
type (high CLDN2, CDH1, RAB25, CLDN3, CDH17 ) are more
resistant and those with a mesenchymal genotype (high CALD1,
VIM, ANK2, ZEB1) display sensitivity. Indeed, GEO tumors pos-
sess an epithelial genotype, requiring a higher concentration of
Table 2 | Inhibition of P-gp increases potency of PF-309.
Cell line PF-309
IC50 nM
PF-309+CP-100356
IC50 nM
DLD-1 278 2.9
Caco-2 300 9.3
HCT15 780 32
LS1034 >1 uM* 796
SW1463 >1 uM* 215
T84 >1 uM* 255
*1 uM was the maximum concentration used. 50% growth inhibition was not
achieved at this concentration.
FIGURE 4 | Knockdown of P-gp by shRNA in DLD-1 cells increased the
potency of PF-3758309. A four to six fold shift in the IC50 was achieved
through the knockdown of P-gp.
PF-309 to achieve effect, while the SW480 tumors possess a mes-
enchymal genotype, requiring a lower concentration of PF-309 to
achieve effect (Figures 5, 7, and 8). Going back and looking at the
in vitro data, we see that two lines where the absence of ABCB1
expression did not predict PF-309 activity, HT29, and NCI-H508,
resistance may be explained by an epithelial genotype (Figures 1
and 8). Interestingly, in the panel of CRC cell lines, we also found
that ABCB1 expression significantly correlated with the epithelial
genotype (p< 0.001, Figure 8A). This association may be an area
of research worth further investigation.
The identification of patient populations expected to derive the
greatest benefit from new therapies is a critical component in the
development of molecularly targeted agents (Banck and Grothey,
2009; Prenen et al., 2010; Siddiqui and Piperdi, 2010; Heakal et al.,
2011; Shaw et al., 2011). However, we must be careful not to ignore
the need for adequate delivery of drug to tumors and the role that
MDR proteins can play in this. The efficacy of compounds that
are substrates for P-gp are not always highly affected by the pres-
ence of P-gp (Jang et al., 2001a), and we speculate that efficacy of
PF-309 may be more greatly affected by the presence of P-gp due
to it being a poorly permeable compound, although this is an area
that requires further study (Feng et al., 2008; Sugano et al., 2010).
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FIGURE 5 | Correlation ofABCB1 andABCG2 expression and tumor
growth inhibition in in vivo CRC cell line xenograft models. (A)
Percent tumor growth inhibition of 11 CRC cell line xenograft models
treated orally with 25 mg/kg PF-309 twice daily. Percent growth inhibition
was calculated from end of study tumor volumes in control and treated
animals. *p<0.05 for end of study tumor volumes treated versus control.
(B) A heatmap for ABCB1 and ABCG2 expression in the tumor xenografts
was generated from data acquired from baseline tumor samples (red
represents high expression and green represents low). Spearman
correlation of ABCB1 relative expression and % growth inhibition showed
a significant correlation (p=0.02), while ABCG2 did not (p=0.7). Tumor
models that were unresponsive to treatment (growth inhibition <40%)
had high relative levels of ABCB1. Conversely, the most responsive tumors
had statistically significant differences between controls and treated
groups, had average growth inhibition >40% and displayed relative low
ABCB1 levels.
FIGURE 6 | In vivo efficacy of PF-309 in CRC PDTX models. Percent
tumor growth inhibition of 12 CRC PDTX models treated orally with
25 mg/kg PF-309 twice daily. Percent growth inhibition was calculated from
end of study tumor volumes in control and treated animals. *p<0.05 for
end of study tumor volumes treated versus control. A range of responses
was observed similar to what was observed in the cell line xenograft
models.
Furthermore, total plasma concentrations of PF-309 were around
10–100 nM at the Cmax (1 h) and 1–10 nM at the trough (6–8 h),
which may not be sufficient to saturate P-gp efflux to allow greater
intracellular accumulation.
Significant effort has been made in the development of agents
to reverse or inhibit the effects of efflux transporters in order to
restore or improve sensitivity of known substrates (Robert, 1999;
Gottesman et al., 2002; Leonard et al., 2003). However, these efforts
have thus far not been highly successful (Ries and Dicato, 1991;
Table 3 | End of study tumor and plasma concentrations of PF-309.
CRC tumor
model
% Growth
inhibition
Tumor
(ng/g)*
Plasma
(ng/mL)
Tumor: plasma
ratio*
CUCRC042 52 34.8 1.17 29.8
29.6 4.58 6.46
Colo201 45 140.4 20.9 6.72
11.1 11.7 0.95
GEO 42 10.2 5.48 1.9
15.9 54.1 0.3
22.9 76.6 0.3
CUCRC036 35 65.7 40.6 1.62
30.7 110 0.28
47.6 81.3 0.59
CUCRC006 32 3.6 42.4 0.08
3.4 24.4 0.14
CUCRC026 30 6.4 25.4 0.25
14.5 114 0.13
22.7 69.3 0.33
16.8 184 0.09
HCT15 18 6.8 10.0 0.68
8.9 13.2 0.67
8.0 49.0 0.16
CUCRC047 −24 4.4 110 0.04
7.5 98.7 0.08
*p<0.003 vs. % growth inhibition.
Dalton et al., 1995; Weinlander et al., 1997; Warner et al., 1998).
We feel that for compounds such as PF-309, strong transporter
substrates with poor permeability characteristics, a reasonable
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FIGURE 7 | Decreased tumor concentration of PF-309 corresponds
with tumor P-gp expression in vivo. (A) Tumor concentrations of
PF-309 were measured 6 h post treatment of a single 25 mg/kg dose.
Higher concentrations of PF-309 were measured in HCT116 and GEO
tumors than SW480 and HCT15 tumors. (B) Western blots were
performed to determine the presence or absence of P-gp in tumors.
Corresponding with the higher concentrations observed in HCT116 and
GEO tumors, no P-gp was detected. And, in the SW480 and HCT15
tumors where lower concentrations of PF-309 were determined, P-gp
was detected.
FIGURE 8 | Heatmaps ofABCB1 expression and epithelial and
mesenchymal genomic signatures. Determination of epithelial (E) signature
was based on expression of CLDN2, CDH1, RAB25, CLDN3, and CDH17.
Mesenchymal (M) signature was based on expression of CALD1, VIM, ANK2,
and ZEB1. Again, red indicates high expression and green, low. (A) ABCB1, E,
and M expression for in vitro CRC cell lines used in these studies.
Interestingly, we found a significant correlation between ABCB1 expression
and the epithelial signature (p< 0.001). For some of the cell lines that
exhibited resistance to PF-309 but did not have high relative ABCB1
expression, resistance may be attributed to an epithelial genotype. (B)
ABCB1, E, and M expression for the 11 in vivo CRC cell line xenografts. No
significant correlation between ABCB1 and E-type was observed here.
alternative to P-gp reversal may be to use patient P-gp status,
in conjunction with other molecular classifiers of resistance (i.e.,
our epithelial/mesenchymal classifier for PF-309), to negatively
select patients for therapy. Given the data presented here and
in our companion paper (Pitts et al., 2013) we do not feel that
we can predict which may play a larger role in resistance, P-gp
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or the epithelial phenotype. We feel that they must be evaluated
together. Tumors that express high P-gp and an epithelial phe-
notype should be excluded from therapy and those with low/no
P-gp and a mesenchymal phenotype should be included. In the
other groups (High P-gp+M-type, Low P-gp+ E-type) the data
is less clear; for instance, it appears that if an m-phenotype exists
cells/tumors are inherently more sensitive to PF-309 and therefore
P-gp may not be as large of a barrier because extremely low concen-
trations are capable of inhibiting growth. Although we suggest that
negative patient selection may be warranted for PF-309, we also
recognize that upregulation of MDR transporters can occur fol-
lowing the initiation of therapy, which would lead to the eventual
resistance to PF-309. Another alternative would be to investigate
the use of PF-309 in cancer types, such as lung carcinomas, where
PAKs play a role in disease progression, but transporter expression
is generally low (Linn and Giaccone, 1995; Ong et al., 2011).
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